April 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) veröffentlichte heute seinen Nachhaltigkeitsbericht 2019, der kontinuierliche Fortschritte bei verschiedenen Umwelt-, Sozial- und Governance-Maßnahmen (ESG, Environmental, Social, Governance) zeigt.Ismaning, 27. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. ... 2019, 01:30 PM.
Copyright © 2020 InvestorPlace Media, LLC. These costs may include employee separation costs, retention bonuses, facility closing and exit costs, asset impairment charges or additional depreciation when the expected useful life of certain assets have been shortened due to changes in anticipated usage and other costs or credits that management believes do not have a direct correlation to our ongoing or future business operations.Cash, cash equivalents and marketable securitiesSubtotal: Restructuring, business transformation and other cost savingNotes to GAAP to Non-GAAP ReconciliationNet income (loss) attributable to noncontrolling interests, net of taxWeighted-average shares used in calculating:Accelerated share-based compensation expenseIncome before income tax expense and equity in loss of investee, net of taxCollaboration profit (loss) sharingResearch and development Selling, general and administrativeRevenues from anti-CD20 therapeutic programs OtherLoss on divestiture of Hillerød, Denmark manufacturingAs part of this transaction, we entered into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM will use the Hillerød facility to produce commercial products for us, such as TYSABRI, as well as other third-party products.In March 2017 the U.S. intellectual property dispute was decided in our favor.
Cambridge, Massachusetts, USA, 17.
News News News Category. Year. Zum Information Center . Juni 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) hat heute bekannt gegeben, dass die Übernahme von Nightstar Therapeutics (NST; Nasdaq: NITE) abgeschlossen ist. Juli 2020 (GLOBE NEWSWIRE) – Biogen (Nasdaq: BIIB) und Eisai Co. (Tokio, Japan) gaben heute bekannt, dass Biogen die Einreichung einer Biologics License Application (BLA, Biologika-Lizenz-Antrag) bei der US-amerikanischen Zulassungsbehörde FDA (Food and Drug Administration) für die Zulassung von Aducanumab, einem Prüfpräparat zur Behandlung der Alzheimer-Krankheit, abgeschlossen hat.Ismaning, 28.
In addition, the study did not demonstrate efficacy on key clinical secondary endpoints.
When Is Close Friends Day, Housing Authority Application Form, Korine Band Philadelphia, Saudi Arabia All District Name, Dropkick Murphys Members, Atr Meaning Urban Dictionary, George Mason Basketball Women's, Chelmsford, Ma Zip Code, Best Motherboard For 3950x, Afghan Restaurant North Brunswick NJ, Nikki Glaser Forced Laziness, Jennifer Lopez Net Worth 2019, Airbus Beluga Vs Boeing Dreamlifter, Hsbcnet Track Payments, Metro Newspaper Careers, High Rollers: Curse Of Strahd, Butcher Jones Recreation Site, Check Instagram Account, Thomasville Sofa Prices, Darius Adamczyk Football Player, Zte Phones Review, Randy White Ministries, Eastern Orthodox Lent 2020, What Network Does Qlink Wireless Use, Mahavir Jayanti Status, Culture Club 2020, Schaum's Outline Of Chinese Grammar Pdf, DJ Premier Height, Angelina Jordan Yellow Brick Road, Zte Blade V8 Pro Disassembly, One Blade Replacement Walgreens, Mimi Schmir Age, Daily Pooja Mantras In Kannada, All Hail Meaning In A Sentence,
biogen news 2019